Domainex is a leading, multi-award-winning, integrated medicines research service partner which provides tailored discovery solutions from target expression to the identification of pre-clinical candidates.
Our world-leading experts accelerate research projects by combining a problem-solving approach with cutting-edge technologies such as PureDiscTM and Direct-to-Biology. With deep expertise across a wide range of target classes and therapeutic areas, and a core focus on the hit identification and hit-to-lead stages, we deliver high-quality results that support confident, timely decision-making for our partners. Domainex operates from state-of-the-art facilities in Cambridge, UK.
Further information about Domainex and its award-winning lead discovery services can be found at www.domainex.co.uk.
Domainex and Vipergen collaboration to offer streamlined hit identification to validated lead series
Vipergen and Domainex have entered into a strategic collaboration to provide an integrated, end-to-end hit and lead discovery offering – combining Vipergen’s cell-based and in vitro DEL screening platforms with Domainex’s expertise in assay development, biophysics, and medicinal chemistry. Together, the two companies cover the full early discovery workflow from hit identification through orthogonal validation and into lead optimization, helping clients accelerate their drug discovery programmes.
Read the full press release here.
